• Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility
• The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables
• These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures

Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair value of its 45% ownership stake in GMP Biotechnology Limited at approximately $388 million, signaling relative stability during a period in which many emerging biotech valuations have faced significant downward pressure (ibn.fm/zeoOT).

“We believe the first quarter of 2026 continues to provide validation for the strategic value of our diversified biotechnology platform,” said Dr. Vuong Trieu, CEO of Oncotelic. “During the quarter, we continued advancing our oncology and AI-enabled development initiatives while maintaining the previously established fair value assessment of our GMP Bio joint venture interest as disclosed in our U.S. Securities and Exchange Commission (“SEC”) filing.”

The valuation was derived from an independent ASC 820 Level 3 assessment that incorporated discounted cash flow methodologies alongside market comparable analysis. Notably, the company reported that no valuation adjustment was necessary during the quarter despite broader volatility affecting small-cap biotechnology and healthcare equities.

Unlike many early-stage biotech companies that rely heavily on recurring equity dilution to fund operations, Oncotelic has pursued a more partnership-driven strategy. Its GMP Biotechnology joint venture structure allows the company to leverage shared development infrastructure, in-house GMP manufacturing capabilities, and collaborative financing mechanisms designed to reduce direct operating cash demands. As a result, this model has helped the company maintain a comparatively modest cash burn profile relative to many traditional clinical-stage biotech peers pursuing fully internal development programs.

Investor interest also continues to center on the company’s broader pipeline potential. Previous third-party analysis from Frost & Sullivan estimated the combined valuation potential of Oncotelic’s pipeline assets at more than $1.7 billion, highlighting the scale of opportunity across its oncology and rare disease programs (ibn.fm/wBSmO).

As demonstrated by investor interest in platform-driven biotechnology companies such as Northwest Biotherapeutics (OTC: NWBO), CytoDyn (OTC: DYDY), Sangamo Therapeutics (OTC: SGMO), and most recently Insilico Medicine (OTC: ISLMF)—which completed the largest biotechnology IPO in Hong Kong in 2025 and achieved a market capitalization exceeding US$2 billion following its public debut—investors continue to assign significant value to companies built around differentiated therapeutic and technology platforms rather than a single product opportunity.”

At the center of the company’s portfolio is OT-101 (Trabedersen), a first-in-class antisense RNA therapeutic targeting TGF-beta2, a pathway associated with tumor immune evasion and disease progression. The therapy has been evaluated across multiple cancer indications, including glioblastoma, pancreatic cancer, colorectal cancer, melanoma, and diffuse intrinsic pontine glioma (“DIPG”), a rare and aggressive pediatric brain cancer for which the company has received rare pediatric disease designation. OT-101 is currently advancing through later-stage development programs and combination studies involving checkpoint inhibitors and IL-2 immunotherapy approaches.

Beyond OT-101, Oncotelic maintains a diversified pipeline that includes CA4P, a vascular disrupting agent being explored for melanoma and solid tumors, OXi4503 for leukemia indications, and AL-101, an intranasal apomorphine candidate targeting Parkinson’s disease, erectile dysfunction, and female sexual dysfunction through the FDA’s 505(b)(2) regulatory pathway. The company has also expanded into nanoparticle delivery technologies and AI-enabled drug development initiatives through its proprietary PDAOAI platform, which is designed to support regulatory workflows, data analysis, and therapeutic discovery efforts.

The company’s strategy reflects growing industry interest in combining artificial intelligence with precision medicine and targeted therapeutics. Management believes this integrated approach could help accelerate development timelines while improving capital efficiency across multiple programs. Broader industry research continues to suggest that AI-driven drug discovery platforms may play an increasingly important role in reducing development costs and streamlining therapeutic identification in future biotechnology pipelines.

At the same time, the company’s regulatory filings provide important context for investors evaluating the story. Because the GMP Biotechnology stake is categorized as a Level 3 asset under ASC 820 accounting standards, the valuation relies heavily on internal assumptions and financial modeling rather than active public market pricing. In addition, the company continues to manage debt obligations and has included going-concern disclosures that are common among development-stage biotech firms. These factors remain important considerations when assessing the company’s overall risk profile and long-term investment potential.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN